Jonas-De-Souza.jpgicon175x175ITM Investigator Jonas de Souza, MD, MBA, discusses the future of immunotherapy in head and neck cancer on OncLive. Read more about de Souza’s ITM-funded cancer research here.

We now have clinical trials assessing the first line: whether immunotherapy should compare head-to-head with our standard extreme regimen. I think that will be the next step–whether immunotherapy is active, and its efficacy in the first line for metastatic patients.

Click Here to Read More

Source: OncLive